#1
#1 out of 1
business11h ago
MedX Health 2025 YEAR REVIEW
- MedX reports over CAD$2 million invested in platform, IP, and compliance to ready the business for large-scale roll-out in 2026.
- DermSecure’s image database grew to approximately 85,000 clinically reviewed images to support AI and clinical decision-making.
- MedX appointed a new CEO and CTO in 2025 to lead technology and strategic efforts.
- A new Chief Operating Officer joined in Q3 2025 to strengthen operations ahead of broader deployment.
- Phase 1 2026 rollout with Health Partners’ employer groups is planned to begin in Q1 2026.
- Oralase, LumaVet, and SIAscopy IP expansion support wider market opportunities in 2026.
- CRO services grew with 26+ CROs across multiple jurisdictions during 2025.
- MedX exited a prior exclusive license with Procter & Gamble in Q1 2025 to pursue broader licensing opportunities.
- The 2025 outlook focuses on platform development, IP reinforcement, and operational readiness for 2026 expansion.
Vote 0